Display options
Cite
Roh J, Jeon Y, Lee AN, et al. The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. Oncotarget. 2017;8(35):58122-58132doi: 10.18632/oncotarget.19468.
Roh, J., Jeon, Y., Lee, A. N., Lee, S. M., Kim, Y., Sung, C. O., Park, C. J., Hong, J. Y., Yoon, D. H., Suh, C., Huh, J., Choi, I., & Park, C. S. (2017). The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. Oncotarget, 8(35), 58122-58132. https://doi.org/10.18632/oncotarget.19468
Roh, Jin, et al. "The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma." Oncotarget vol. 8,35 (2017): 58122-58132. doi: https://doi.org/10.18632/oncotarget.19468
Roh J, Jeon Y, Lee AN, Lee SM, Kim Y, Sung CO, Park CJ, Hong JY, Yoon DH, Suh C, Huh J, Choi I, Park CS. The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. Oncotarget. 2017 Jul 22;8(35):58122-58132. doi: 10.18632/oncotarget.19468. eCollection 2017 Aug 29. PMID: 28938542; PMCID: PMC5601638.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 22;8(35):58122-58132. doi: 10.18632/oncotarget.19468. eCollection 2017 Aug 29.

The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma.

Oncotarget

Jin Roh, Youkyoung Jeon, A-Neum Lee, Sang Min Lee, YeonMee Kim, Chang Ohk Sung, Chan-Jeoung Park, Jung Yong Hong, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh, Inhak Choi, Chan-Sik Park

Affiliations

  1. Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
  2. Department of Microbiology and Immunology, Advanced Research Center for Multiple Myeloma, Inje University College of Medicine, Busan, Korea.
  3. Asan Institute for Life Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
  4. Cell Dysfunction Research Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
  5. Department of Hematology/Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
  6. Department of Pathology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
  7. Department of Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
  8. Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

PMID: 28938542 PMCID: PMC5601638 DOI: 10.18632/oncotarget.19468

Abstract

Multiple myeloma (MM) remains as an incurable disease, despite recent substantial improvements in treatment. Therefore, development of novel biomarkers for risk stratification and new therapeutic targets are imperative. One of the emerging treatments for MM is the immune checkpoint blockades. V-set Ig domain-containing 4 (VSIG4) is a lately studied B7-related immune checkpoint modulator. We assessed the VSIG4 expression in patients with MM and its prognostic impact. We analyzed 81 bone marrow and 66 extramedullary biopsy samples of MM patients using immunohistochemistry. VSIG4 mRNA expression data from the Multiple Myeloma Genomics Portal (MMGP) were analyzed to validate our results. The overall survival (OS) of the high VSIG4 expression group was significantly poorer than that of the low VSIG4 expression group (

Keywords: VSIG4; immune checkpoint; immunohistochemistry; multiple myeloma; prognosis

Conflict of interest statement

CONFLICTS OF INTEREST All the authors declare that they have no conflicts of interest.

References

  1. N Engl J Med. 2013 Jul 11;369(2):122-33 - PubMed
  2. Lab Invest. 2014 Jul;94(7):706-15 - PubMed
  3. Cancer Res. 2006 Apr 1;66(7):3381-5 - PubMed
  4. Hepatology. 2012 Nov;56(5):1838-48 - PubMed
  5. Cancer Res. 2003 Oct 1;63(19):6501-5 - PubMed
  6. J Leukoc Biol. 2006 Oct;80(4):922-8 - PubMed
  7. J Cancer Res Clin Oncol. 2008 Sep;134(9):1021-7 - PubMed
  8. Biochim Biophys Acta. 2000 Jul 24;1492(2-3):522-5 - PubMed
  9. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  10. Clin Immunol. 2010 Aug;136(2):282-91 - PubMed
  11. Ann Ist Super Sanita. 2016 Apr-Jun;52(2):213-22 - PubMed
  12. Leukemia. 2009 Dec;23(12):2210-21 - PubMed
  13. J Immunol. 2015 Mar 15;194(6):2855-61 - PubMed
  14. Am J Hematol. 2014 Oct;89(10):999-1009 - PubMed
  15. J Immunol. 2010 Sep 1;185(5):2747-53 - PubMed
  16. Leukemia. 2014 May;28(5):993-1000 - PubMed
  17. Clin Cancer Res. 2008 May 15;14(10):3044-51 - PubMed
  18. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  19. PLoS One. 2012;7(12):e51862 - PubMed
  20. Toxins (Basel). 2014 Mar 03;6(3):914-33 - PubMed
  21. Clin Cancer Res. 2015 Oct 15;21(20):4607-18 - PubMed
  22. Clin Cancer Res. 2013 Mar 1;19(5):997-1008 - PubMed
  23. Am J Transl Res. 2015 Jun 15;7(6):1172-80 - PubMed
  24. J Immunol. 2003 Feb 1;170(3):1257-66 - PubMed
  25. Cell. 2006 Mar 10;124(5):915-27 - PubMed
  26. Clin Cancer Res. 2004 Aug 1;10(15):5094-100 - PubMed
  27. Am J Pathol. 2011 Sep;179(3):1310-8 - PubMed
  28. Blood. 2015 May 14;125(20):3076-84 - PubMed
  29. Blood. 2007 Feb 15;109(4):1669-77 - PubMed
  30. Cancer. 2010 Apr 1;116(7):1757-66 - PubMed
  31. Mayo Clin Proc. 2013 Apr;88(4):360-76 - PubMed
  32. Br J Haematol. 2013 Aug;162(3):313-25 - PubMed
  33. Lancet Oncol. 2014 Nov;15(12):e538-48 - PubMed
  34. Nat Rev Clin Oncol. 2011 Apr 26;8(8):479-91 - PubMed
  35. J Clin Invest. 2006 Oct;116(10):2817-26 - PubMed
  36. Cancer Cell. 2006 Apr;9(4):313-25 - PubMed
  37. J Clin Oncol. 2005 Sep 10;23(26):6333-8 - PubMed
  38. Nat Med. 2002 Aug;8(8):793-800 - PubMed
  39. N Engl J Med. 2012 Jun 28;366(26):2455-65 - PubMed
  40. Cancer Control. 2014 Jul;21(3):231-7 - PubMed

Publication Types